Posted by Michael Wonder on 08 May 2026
Rznomics announces US FDA regenerative medicine advanced therapy designation granted to RZ-001 for hepatocellular carcinoma
8 May 2026 - RMAT designation based on promising Phase 1b/2a clinical data, including safety profile and preliminary response rates, with trans-splicing ribozyme-based RNA editing platform.
Rznomics announced today that the US FDA has granted regenerative medicine advanced therapy designation to RZ-001, its lead investigational candidate for the treatment of hepatocellular carcinoma.
